Liraglutide enhances insulin secretion and prolongs the remission period in adults with newly diagnosed type 1 diabetes (the NewLira study): A randomized, double-blind, placebo-controlled trial

Nombre investigadores: Thomas F Dejgaard, Christian S Frandsen, Urd Kielgast, Joachim Størling, Anne J Overgaard, Maria S Svane, Markus Harboe Olsen, Birger Thorsteinsson, Henrik U Andersen, Thure Krarup, Jens J Holst, Sten Madsbad